Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline - Wikidata - awgldk - TriplyDB

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

http://www.wikidata.org/entity/Q28079118

about

Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives Recent advances in the medical treatment of breast cancer Future microfluidic and nanofluidic modular platforms for nucleic acid liquid biopsy in precision medicine.Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.Making Meaningful Clinical Use of Biomarkers Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data.Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts.Genomic Disparities in Breast Cancer Among Latinas.What the blood knows: interrogating circulating tumor DNA to predict progression of minimal residual disease in early breast cancer.Competing endogenous RNA network analysis identifies critical genes among the different breast cancer subtypes.Diagnostic and prognostic value of serum MACC1 in breast cancer patients.Epidemiology and survival outcome of breast cancer in a nationwide study.Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.Genomic Evolution of Breast Cancer Metastasis and Relapse.Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions.CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.Clinical utility of gene-expression signatures in early stage breast cancer.Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.Hormone-receptor positive breast cancer: highlights from the 39TH San Antonio Breast Cancer Symposium.Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer.The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment.News on the medical treatment of young women with early-stage HER2-negative breast cancer.Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.Extended Endocrine Therapy: Is 5 Years Enough?An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.Unsupervised Clustering of Quantitative Image Phenotypes Reveals Breast Cancer Subtypes with Distinct Prognoses and Molecular Pathways.A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry.Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer.Prognostic Value of Circulating Tumor Cells Identified Before Surgical Resection in Nonmetastatic Breast Cancer Patients.Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor-Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint.Best Practices for Genomic Assay Testing in Early-Stage Breast Cancer: Clinical and Medicolegal Perspectives.

P2860

Q26741009-958309F4-D2C3-434F-B88F-DA6D5122813E Q28078951-D5DD8157-4E2F-42BF-8C20-2DDB38FA4BC2 Q30357091-6A6A8AB2-9ED3-4F4B-A667-80BAA2F3C84F Q31098350-5B548A09-A95A-4227-ABDF-6B9C9DF00FEC Q31167768-9EC0BFB7-886A-4896-9040-889D3ABFD2C4 Q33591751-E4EF1A63-18D8-4EAE-BAFF-EB85D2F318AB Q33660598-BB6B7163-34F8-4F80-8472-29769FEE137A Q33756398-4571A94C-704E-42B3-9210-628FE90137AD Q33821481-41E91CFB-B9F1-4F17-8C53-C1C5A3D74F2F Q36334258-4C54F221-49E2-4A93-8A29-DE043625A029 Q36379148-F9CB53EF-399D-47D0-AA4D-1C61E9E73922 Q37509093-8422D4AB-6125-4636-9493-9007C4883585 Q37583778-BE40D63C-1377-459D-A778-B293032410F5 Q37705802-3C3F3F39-D5DD-45AC-8DC7-C72F8B917BEC Q37708960-98E163D9-30F0-44A4-BA2F-4CC1A4A18F38 Q37725545-213EA6D9-2E05-4A48-8DEB-68620DEBE960 Q38599649-F8E181B6-92F2-41E6-8699-87F65381933C Q38623761-DD875E68-F355-4109-B68A-3AF7C3746E4F Q38639746-AFA63737-D570-4640-878C-D3694AE2B875 Q38668766-3A275263-2441-41D7-A614-011FCBC90115 Q38686476-BBE01873-092B-4A95-8F8D-C2BC129CF60F Q38711157-FDBBF28B-136A-483C-81F6-FB5E3D14B4A7 Q38745404-5A2C5CEF-024B-4042-B978-A9A35D6207BE Q38754717-F3FEE8C4-0830-4496-B85F-66067E3701EA Q38761797-CA7F717F-567F-4C1F-9307-69C1E5A73445 Q38798302-45165F42-DD4E-41B5-AE67-3D217FF8B745 Q38805436-A34C4BB9-9BCA-4F00-99F8-01614C8D74F0 Q38846639-8675DC58-AB3E-4035-A5E8-3B9DA18FC85C Q38870541-230696A0-6496-4E13-87C9-39A93702D47E Q38933874-8E5353DC-C9B0-461C-ACC4-9449407308D2 Q38934318-76E65AE8-C560-406A-A85D-3CF91328A3B1 Q39015485-E9098E90-D987-46AA-A908-6B5B839E7D79 Q39028398-B9A9F88D-2700-4111-A1A5-EE2B1AB2CC6F Q39141610-D0A934B2-874D-4EB1-B5A5-6C1CEBD1AD9B Q39187437-426CC69D-22AE-48AD-8DF4-7080667D0C1C Q39243861-4F4B93FE-976A-425D-97D6-4B7B9E3E8C80 Q39254713-5D594050-75F6-4C38-BD02-7C760A025EAA Q39859646-D44C1639-6C9A-45EA-8609-55E5D16F5D39 Q41443052-7EFEF8F3-F518-4763-9012-94FA0C91FF67 Q41467691-82482B44-E264-4D78-BE81-CCDEAE36548B

P2860

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

http://www.wikidata.org/entity/Q28079118

description

2016 nî lūn-bûn

@nan

2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Use of Biomarkers to Guide Dec ...... gy Clinical Practice Guideline

@ast

Use of Biomarkers to Guide Dec ...... gy Clinical Practice Guideline

@en

Use of Biomarkers to Guide Dec ...... gy Clinical Practice Guideline

@nl

type

label

Use of Biomarkers to Guide Dec ...... gy Clinical Practice Guideline

@ast

Use of Biomarkers to Guide Dec ...... gy Clinical Practice Guideline

@en

Use of Biomarkers to Guide Dec ...... gy Clinical Practice Guideline

@nl

prefLabel

Use of Biomarkers to Guide Dec ...... gy Clinical Practice Guideline

@ast

Use of Biomarkers to Guide Dec ...... gy Clinical Practice Guideline

@en

Use of Biomarkers to Guide Dec ...... gy Clinical Practice Guideline

@nl

P1433

Q28079118-A1A70EC6-239C-4245-919D-7C00B84F66A7

P1476

Q28079118-9BB7049A-3E32-48C9-9845-218DC6D1F373

P2093

Q28079118-2143D30B-C5E9-4366-ADAF-28C1446A6ED2

Q28079118-36E702FD-50DB-434A-BA22-0CAA633D654A

Q28079118-4454E768-3FA8-4466-A9A0-FE29D572EFC2

Q28079118-56919610-5063-4285-8C25-53BCB87B95F6

Q28079118-86E0BF3D-5432-4F84-AD86-A9FD30CA4AE2

Q28079118-8803BB44-B396-4FB3-819A-93CF75271F12

Q28079118-A3417149-E202-48BA-A0EF-EF452B022D07

Q28079118-C3DEF014-2436-4D22-AD19-817EDA1E2D85

Q28079118-D1519101-8373-482C-9779-79752320706E

Q28079118-D7DFBD13-33F6-4F05-BA4B-163E30C72C75

P2860

Q28079118-002ADBF3-781B-44E3-BE4A-AAF3EA9551DF

Q28079118-02C02458-5927-437A-87A4-AB437F30647B

Q28079118-052E635A-CE88-4334-9971-38190DCDAE34

Q28079118-0817E5CC-0260-4B19-A767-285A9FE43254

Q28079118-08687DC6-B552-4551-9A5A-7A76AF024A50

Q28079118-0B39F25C-6CD4-4708-87AF-57D25B05E3CD

Q28079118-0B7E61CD-8717-45F8-84D7-AB9176F3C0A1

Q28079118-0D759E59-095B-440E-AEDA-506BC0DD9124

Q28079118-112AFA78-07D6-4525-9551-33F26F352924

Q28079118-123F0044-6638-4C0F-A18E-21F79BD9F069

P304

Q28079118-41E2F7EB-0B41-4A6B-9B55-A2B30A5B3C1C

P31

Q28079118-6CD20BD0-1CE8-41C4-B9B4-3601E68DDC3C

P3181

Q28079118-83DAF27B-CB8A-4415-9DE2-AC3AA56BFBD2

P356

Q28079118-7234F051-5020-4AF0-802A-C2AE28D92D77

P407

Q28079118-CED1831C-3E51-4240-9165-7466B0DFA37F

P433

Q28079118-60DDF8EB-812B-43E6-805B-271F7CCE1DCC

P478

Q28079118-64743D4C-8656-44DF-9A46-392BBBD0BE58

P50

Q28079118-83928A58-C1FE-4690-A6B4-C523B5668F9E

Q28079118-FB382C43-8737-4240-89C5-D2D87F58E127

P577

Q28079118-7EE97462-9F10-43A2-8908-9D3EB2A44097

P698

Q28079118-59D64171-A947-4EFC-8C78-06320F9F6066

P921

Q28079118-2EE4333A-56E6-42DA-B643-EC81CB7DAC06

P932

Q28079118-2A940A59-20C5-49CE-8603-E41BAF23AE0B

P3181

P356

JCO.2015.65.2289

P1433

Journal of Clinical Oncology

P1476

Use of Biomarkers to Guide Dec ...... gy Clinical Practice Guideline

@en

P2093

American Society of Clinical Oncology

http://www.w3.org/2001/XMLSchema#string

Ana M Gonzalez-Angulo

http://www.w3.org/2001/XMLSchema#string

Catherine Van Poznak

http://www.w3.org/2001/XMLSchema#string

Daniel F Hayes

http://www.w3.org/2001/XMLSchema#string

Deborah E Collyar

http://www.w3.org/2001/XMLSchema#string

Elizabeth H Hammond

http://www.w3.org/2001/XMLSchema#string

Lisa M McShane

http://www.w3.org/2001/XMLSchema#string

Lyndsay N Harris

http://www.w3.org/2001/XMLSchema#string

Minetta C Liu

http://www.w3.org/2001/XMLSchema#string

Nicole M Kuderer

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond.

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Clinical trial designs for predictive marker validation in cancer treatment trials

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.

P304

1134-1150

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1473030

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2015.65.2289

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26858339

http://www.w3.org/2001/XMLSchema#string

P921

P932

4933134

http://www.w3.org/2001/XMLSchema#string